Amneal Pharmaceuticals Inc

1. 1

   Election of Directors

   ManagementBoard: FOR

   Election of the 10 nominees named in the proxy statement to serve until the next annual meeting and until their successors are elected and qualified.

2. 2

   Advisory Vote on Executive Compensation (Say-on-Pay

   ManagementBoard: FOR

   Advisory (non-binding) proposal to approve the compensation of the Company's named executive officers as disclosed in the proxy statement.

   More detail

   This proposal requests a non-binding, advisory vote to approve the compensation paid to the Company’s named executive officers as disclosed in the proxy statement. Management seeks shareholder approval to validate its pay-for-performance framework, which ties substantial portions of pay to adjusted EBITDA targets, annual cash incentives, PSUs linked to multi-year absolute stock price growth, and RSUs that promote retention. The Compensation Committee uses peer benchmarking, an independent consultant, and company-specific financial metrics (notably adjusted EBITDA) to set targets and determine awards; the committee also considered the strong 99.4% support in last year’s say-on-pay vote as indicative of shareholder alignment. The advisory vote does not alter current compensation arrangements if it fails, but the Board and Compensation Committee state they will consider the outcome and shareholder feedback when making future compensation decisions. Management emphasizes that its compensation design balances short-term operational incentives with long-term equity-based alignment, including multi-year PSUs with absolute stock-price growth hurdles that vest over three years, and annual bonuses with adjusted EBITDA company performance multipliers. The Board’s recommendation to vote FOR is grounded in the belief that the program attracts and retains leadership, drives execution of strategy (including growth in Specialty, biosimilars, and AvKARE distribution), and aligns executive interests with stockholder value creation through measurable financial and stock-performance conditions. Key contextual factors include the Company’s recent financial performance (8% revenue growth, improved adjusted EBITDA), refinancing to extend maturities to 2032, and ongoing strategic moves into biosimilars and higher-barrier product categories that management says justify incentive structures focused on long-term value. Investors should note the advisory and non-binding nature of the vote, the Compensation Committee’s use of discretion in individual multipliers, and the absence of a direct link to clawbacks beyond the Company’s adopted Clawback Policy; these governance features and compensatory levers will be material inputs for analysts evaluating the efficacy of the program relative to peers and risks associated with execution and regulatory outcomes.

3. 3

   Ratification of Appointment of Independent Registered Public Accounting Firm

   ManagementBoard: FOR

   Ratify the appointment of Ernst & Young LLP as the Company's independent registered public accounting firm for fiscal year 2026.

Upcoming shareholder meetings at Amneal Pharmaceuticals Inc’s closest sector peers — compare boards, ballots, and ownership across the cohort.

When is the Amneal Pharmaceuticals Inc 2026 annual meeting?

Amneal Pharmaceuticals Inc (AMRX) holds its 2026 annual shareholder meeting on Wednesday, May 6, 2026.

What is the record date for the Amneal Pharmaceuticals Inc 2026 meeting?

The record date for the Amneal Pharmaceuticals Inc 2026 meeting is Thursday, March 12, 2026. Shareholders of record on or before that date are eligible to vote.

Who are the director nominees for Amneal Pharmaceuticals Inc's 2026 meeting?

The board is presenting 10 director nominees at the Amneal Pharmaceuticals Inc 2026 meeting, listed with their independence status and background.

What proposals will shareholders vote on at the Amneal Pharmaceuticals Inc 2026 meeting?

Shareholders will vote on 3 proposals at the Amneal Pharmaceuticals Inc 2026 meeting, each tagged with who proposed it and the board's recommendation.